Regeneron Pharmaceuticals, Inc. (REGN) is a Healthcare company in the Biotechnology industry with a 84% Strong Buy Score. Key strengths include Gross Margin (44.6%), Net Margin (31.4%), Return on Equity (14.9%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.
This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.
See how our AI analyzes REGN fundamentals to generate buy/sell signals and Strong Buy Scores.
Our AI evaluates Regeneron Pharmaceuticals, Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Strong Buy rating:
Key developments and data points that may impact Regeneron Pharmaceuticals, Inc.'s trajectory:
How Regeneron Pharmaceuticals, Inc. stacks up against comparable Healthcare companies on key metrics:
Every investment carries risk. Here are the specific risk factors our analysis identified for Regeneron Pharmaceuticals, Inc.:
Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.
A snapshot of Regeneron Pharmaceuticals, Inc.'s financial health based on the most recent filings:
Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.
Based on our AI-powered fundamental analysis, REGN has a Strong Buy Score of 84%, earning a "Strong Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.
Regeneron Pharmaceuticals, Inc. demonstrates robust fundamentals across multiple categories. Key strengths include Gross Margin (44.6%) and Net Margin (31.4%). The stock shows characteristics typically associated with outperformers.
Our AI analyzes Regeneron Pharmaceuticals, Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 84% score:
Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.
Technical traders can view real-time demand and supply zones for REGN on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.
With REGN currently trading at $751.97, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.
Subscribe to demand zone alerts to receive real-time notifications when REGN reaches key technical levels.
Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector, specifically in Biotechnology. Understanding earnings trends is crucial for forecasting REGN's trajectory.
Current revenue growth of 2.5% slightly beats the average company.
Visit our Earnings Calendar to track upcoming REGN earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.
Our AI projects REGN's trajectory based on current fundamentals and historical patterns. With a 84% Strong Buy Score, here's what the data suggests:
Bullish Outlook: Regeneron Pharmaceuticals, Inc. shows strong fundamental momentum. Net margins of 31.4% indicate pricing power and operational efficiency. Stocks with similar profiles have historically outperformed over 12-month periods.
For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.
Understanding valuation is critical for determining if REGN is fairly priced. Here's the current snapshot:
Our AI weighs these metrics against growth rates and margin quality to determine if REGN offers compelling risk-adjusted returns at current prices.
Here's why investors are bullish on Regeneron Pharmaceuticals, Inc.:
With a 84% Strong Buy Score, the bull case is well-supported by current fundamentals. The stock exhibits characteristics of quality compounders that tend to outperform long-term.
Every investment carries risk. Here are potential concerns for REGN investors:
The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.
REGN Summary: Regeneron Pharmaceuticals, Inc. earns a 84% Strong Buy Score based on AI analysis of fundamental data. Trading at $751.97 with a $79.50B market cap, the stock shows strong fundamentals supporting a bullish 12-month outlook.
Bull Case: Gross Margin (44.6%), Net Margin (31.4%)
For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free REGN PDF report.
Deepen your understanding of the concepts used in this REGN analysis:
Learn how to evaluate stocks using financial statements and key metrics.
Understanding P/E RatioWhat P/E ratio tells you about a stock's valuation and growth expectations.
Return on Equity (ROE)Why ROE matters for stock selection and how to interpret it.
Stock Valuation MethodsCompare DCF, P/E, and other approaches to value stocks like REGN.
What Are Demand Zones?Find key support and resistance levels for REGN and other stocks.
How to Read Earnings ReportsUnderstand earnings per share, revenue surprises, and guidance.
Latest SEC filings for REGN explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.